AyuGen has made the newest advances in cancer treatment available for patients in India. This test involve taking the tumor block & analyzing it for multiple genes involved in cancer development, treatment & response to medicines used in cancer. Thus, it helps doctors & patients to use the most appropriate treatment based on the tumor profile. There are two types of tests in this.
OncoDEEP Tests for guiding treatment in cancer OncoDeep tests are useful when first & second line of treatment is failing. There are three types of tests :
1) Oncodeep - It is for all solid tumours preferably the ones that failed after second line of treatment. It is a 65 genes next generation sequencing (NGS) test in which most prevalent mutations associated with drug response are looked for. Each gene in this test has been shown to be altered in cancer, leading to oncogenesis and the response, or lack of response, to several anti-cancer drugs already on the market. The test also includes the relevant IHC (about 8 to 10 depending on the tumor) for targeted therapies & chemotherapy.
2) OncoDEEP & TRACE – It is specifically for metastatic stage III & IV cancer patients whose treatment is failing after second line of treatment. It is a 200+ genes next generation sequencing (NGS) test in which most prevalent mutations associated with drug response are looked for. The test also includes the relevant IHC (about 8 to 10 depending on the tumor) for targeted therapies & chemotherapy. It also includes 183 assays for fusion gene analysis (like ALK, ROS1, RET, NTRK1 etc.). In addition, it will also contain two streck tubes that allows the analysis of the ctDNA by NGS in order to circumvent the tumor and metastases heterogeneity and identify markers associated to resistance and sensitivity to targeted therapies. This OncoTRACE core panel will target 28 hotspots genes and it is also useful to monitor the burden of the disease by adding 12-15 specific variants from the tumor later on.
2) OncoTRACE – It is a NGS test performed on ctDNA (liquid biopsy). This is recommended for samples that have already undergone molecular analyses on the solid tumour. It is customized to include the molecular variations observed in earlier molecular analyses along with 28 hotspot genes. The turn-around-time is about 10 to 15 days.
Sample requirement - Tumor block and blood sample